WCLC 2025 - Posters & ePosters-EP.13.36 Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer

EP.13.36 Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer

Pdf Summary

This retrospective study evaluated the efficacy and safety of induction immunochemotherapy followed by concurrent chemoradiotherapy (CCRT) in patients with limited-stage small cell lung cancer (LS-SCLC). Conducted at Shanghai Pulmonary Hospital, the analysis included 34 patients receiving induction immunochemotherapy plus CCRT and 104 controls treated with induction chemotherapy followed by CCRT. Propensity score matching was used to control for baseline characteristics.<br /><br />Results demonstrated that the objective response rate (ORR) after induction treatment was significantly higher in the immunochemotherapy group (67.6%) compared to chemotherapy alone (45.2%, p=0.023). After CCRT, ORR remained superior at 79.4% versus 60.6% (p=0.045). Median progression-free survival (PFS) was notably longer in the immunochemotherapy group at 21.3 months versus 13.1 months (p=0.007), and overall survival (OS) median was not reached versus 41.7 months (p=0.031). These survival benefits persisted after propensity score matching. Treatment-related adverse events of grade 3-4 severity were comparable between groups (41.2% vs. 41.3%).<br /><br />The study concludes that induction immunochemotherapy followed by CCRT offers improved tumor responses and survival outcomes with a manageable toxicity profile in LS-SCLC patients. The findings support further validation through large-scale randomized controlled trials. This research builds on the established role of durvalumab consolidation in LS-SCLC by exploring immune checkpoint inhibition during the induction phase.<br /><br />Reference: Cheng et al., 2024, NEJM, demonstrated durvalumab benefit post-CCRT in LS-SCLC.  <br />Contact: Prof. Yaping Xu, Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University, China; xuyaping1207@126.com.

Asset Subtitle

Letong Yang

Meta Tag

Speaker Letong Yang

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

limited-stage small cell lung cancer

induction immunochemotherapy

concurrent chemoradiotherapy

objective response rate

progression-free survival

overall survival

propensity score matching

treatment-related adverse events

durvalumab consolidation

immune checkpoint inhibition